Index by author

September 01, 1996; Volume 63,Issue 5

  1. Homler, Howard

    1. Shark cartilage and cancer
      Howard Homler, MD
      Cleveland Clinic Journal of Medicine September 1996, 63 (5) 305;

  2. Homoud, Munther

    1. Strategies for managing atrial fibrillation
      Michael S. Katcher, MD, Caroline B. Foote, MD, Munther Homoud, MD, Paul J. Wang, MD and N.A. Mark Estes, MD
      Cleveland Clinic Journal of Medicine September 1996, 63 (5) 282-294;

      The limitations of current therapies for atrial fibrillation are forcing a rethinking of how they should be used.

  3. Katcher, Michael S.

    1. Strategies for managing atrial fibrillation
      Michael S. Katcher, MD, Caroline B. Foote, MD, Munther Homoud, MD, Paul J. Wang, MD and N.A. Mark Estes, MD
      Cleveland Clinic Journal of Medicine September 1996, 63 (5) 282-294;

      The limitations of current therapies for atrial fibrillation are forcing a rethinking of how they should be used.

  4. Levy, Daniel

    1. Preventive cardiology: Whose job is it? Who will pay for it? What is the best strategy?
      Daniel Levy, MD and Dennis L. Sprecher, MD
      Cleveland Clinic Journal of Medicine September 1996, 63 (5) 275-279;

      Should cardiologists, internists, or nurse practitioners lead prevention efforts? What is the role of diet in the era of the statins?

  5. Long, Geoffrey S.

    1. Interpreting serologic tests for hepatitis C virus infection: balancing cost and clarity
      Geoffrey S. Long, MD, Bruce R. Bacon, MD and Adrian M. Di Bisceglie, MD
      Cleveland Clinic Journal of Medicine September 1996, 63 (5) 264-268;

      ELISA screening tests for HCV have unacceptably high false-positive rates. Newer tests are more accurate, but costly.

  6. Mark Estes, N.A.

    1. Strategies for managing atrial fibrillation
      Michael S. Katcher, MD, Caroline B. Foote, MD, Munther Homoud, MD, Paul J. Wang, MD and N.A. Mark Estes, MD
      Cleveland Clinic Journal of Medicine September 1996, 63 (5) 282-294;

      The limitations of current therapies for atrial fibrillation are forcing a rethinking of how they should be used.

  7. Markman, Maurie

    1. What does tumor shrinkage mean to the patient receiving chemotherapy?
      Maurie Markman, M.D.
      Cleveland Clinic Journal of Medicine September 1996, 63 (5) 301-302;

      Chemotherapy is often considered successful. if the tumor shrinks. But does tumor shrinkage alleviate symptoms and prolong life?

    2. What does tumor shrinkage mean to the patient receiving chemotherapy?
      Maurie Markman, M.D.
      Cleveland Clinic Journal of Medicine September 1996, 63 (5) 301-302;

      Chemotherapy is often considered successful. if the tumor shrinks. But does tumor shrinkage alleviate symptoms and prolong life?

  8. Mcwhinney, Bruce D.

    1. Contemporary issues in cost-effective drug therapy
      Bruce D. McWhinney, PharmD and Morton P. Goldman, PharmD
      Cleveland Clinic Journal of Medicine September 1996, 63 (5) 261-263;

      There is more to controlling pharmacy costs than choosing the least expensive drug. Preventing medication errors and reducing overall costs is key.

  9. Morley, John C.

    1. Health quality data
      John C. Morley and Dwain L. Harper, DO
      Cleveland Clinic Journal of Medicine September 1996, 63 (5) 303-304;

  10. Rogers, Douglas G.

    1. Prevention of insulin-dependent diabetes mellitus: an overview of three trials
      Desmond A. Schatz, MD, Douglas G. Rogers, MD and Ben H. Brouhard, MD
      Cleveland Clinic Journal of Medicine September 1996, 63 (5) 270-274;

      Clinicians are eagerly awaiting the results of three large-scale trials using different approaches to prevent IDDM.

« Previous (Pages : 1 2 3 ... 3) Next »
Back to top

In this issue